Pure Communications, Inc.Kristie Wallis, 646-320-3845orOpGen, Inc.Michael Farmer, 240-813-1284Director of Marketing
today announced that new data on the utility and application of its Whole Genome Mapping™ technology in the public health and health care settings will be highlighted at a company-sponsored symposium and poster presentation during the American Society for Microbiology (ASM) 113 General Meeting. The meeting is being held May 18-21, 2013 at the Colorado Convention Center in Denver. OpGen will be exhibiting at booth #1216 during the conference.
Mike Miller, Ph.D., Associate Director for Laboratory Science (Retired) for the National Center for Emerging and Zoonotic Infectious Diseases, CDC, will present new data on OpGen’s Whole Genome Mapping technology during a poster presentation on Monday, May 19, 2013. The poster titled “Whole Genome Mapping for the Analysis of Bacterial Strains from Foodborne Outbreaks” will highlight the application of the technology in the analysis of food-borne pathogens. The poster provides an overview of the utility of Whole Genome Mapping to quickly analyze and map a multi-state outbreak of ser. Typhimurium associated with contaminated peanut products.
Additionally, OpGen will host a symposium titled “Complete, High Resolution Whole Genome Mapping Applications in Public and Health Care Settings” on Sunday, May 19, 2013 at 7 p.m. M.D.T. at the Hyatt Regency in Denver. The symposium will feature presentations by Dr. Miller; Jack A. Gilbert, Ph.D., principal investigator, Hospital Microbiome Project at Argonne National Laboratory; and Bart Weimer, Ph.D., Director, 100K Pathogen Genome Project, Director, [email protected] and Director, Genomics Integration Core at West Coast Metabolomics Center at the University of California, Davis.
OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services. The company’s Whole Genome Mapping™ Technology, GenomeBuilder™ Software and MapIt Service provide high resolution, whole genome maps for strain typing, sequence assembly and finishing, and comparative genomics in the healthcare, public health, and life sciences markets. OpGen’s powerful technology dramatically improves the quality of data and time-to results by providing sequence information from single DNA molecules more rapidly and less expensively than previously possible. The company is dedicated to positively influencing individual healthcare outcomes, enhancing public health, and advancing scientific research by delivering precise, actionable information and results. OpGen’s customers include federal and state public health centers, hospitals, leading genomic research centers, biodefense organizations, academic institutions, clinical research organizations and biotechnology companies. For more information, visit .